Clinical Trial Update: 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD) [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 open-label safety study of PD-0332334 in elderly patients with Generalized Anxiety Disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: WITHDRAWN